Log In
Print this Print this

Debio 0719

  Manage Alerts
Collapse Summary General Information
Company Kyowa Hakko Kirin Co. Ltd.
DescriptionSelective inhibitor of lysophosphatidic acid receptor 1 (LPAR1) and type 3 (LPA3)
Molecular Target Lysophosphatidic acid receptor 1 (LPAR1) (EDG2) (LPA1) ; Lysophosphatidic acid receptor 3 (LPAR3) (EDG7) (LPA3)
Mechanism of ActionUndisclosed
Therapeutic Modality 
Latest Stage of DevelopmentPreclinical
Standard Indication Cancer (unspecified)
Indication DetailsTreat metastatic cancer
Regulatory Designation
Partner Debiopharm Group

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today